Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1997 1
1998 1
1999 3
2000 8
2001 3
2002 4
2003 6
2004 8
2005 13
2006 4
2007 7
2008 12
2009 19
2010 13
2011 33
2012 33
2013 42
2014 49
2015 40
2016 32
2017 38
2018 30
2019 18
2020 17
2021 20
2022 11
2023 13
2024 14
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Results by year

Filters applied: . Clear all
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.
Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. Wallace BD, et al. Among authors: koo js. Science. 2010 Nov 5;330(6005):831-5. doi: 10.1126/science.1191175. Science. 2010. PMID: 21051639 Free PMC article.
Prognostic factors of breast phyllodes tumors.
Shin E, Koo JS. Shin E, et al. Among authors: koo js. Histol Histopathol. 2023 Aug;38(8):865-878. doi: 10.14670/HH-18-600. Epub 2023 Feb 27. Histol Histopathol. 2023. PMID: 36866915 Review.
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Panaccione R, et al. Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17. Lancet. 2025. PMID: 40684778 Clinical Trial.
The Role of Autophagy in Breast Cancer Metastasis.
Kim HM, Koo JS. Kim HM, et al. Among authors: koo js. Biomedicines. 2023 Feb 18;11(2):618. doi: 10.3390/biomedicines11020618. Biomedicines. 2023. PMID: 36831154 Free PMC article. Review.
Charcoal-induced pseudomelanosis ilei.
Kim SY, Koo JS, Hynun JJ, Jung SW, Choung RS, Yim HJ, Lee SW, Choi JH. Kim SY, et al. Among authors: koo js. Endoscopy. 2011;43 Suppl 2 UCTN:E380. doi: 10.1055/s-0030-1257042. Epub 2011 Dec 2. Endoscopy. 2011. PMID: 22139793 No abstract available.
451 results